BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiang W, Dai Y, Xing X, Sun X. Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. Comput Struct Biotechnol J 2021;19:1263-76. [PMID: 33717423 DOI: 10.1016/j.csbj.2021.01.046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Peng G, Chi H, Gao X, Zhang J, Song G, Xie X, Su K, Song B, Yang J, Gu T, Li Y, Xu K, Li H, Liu Y, Tian G. Identification and validation of neurotrophic factor-related genes signature in HNSCC to predict survival and immune landscapes. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1010044] [Reference Citation Analysis]
2 Chen J, Li S, Huang Z, Cao C, Wang A, He Q. METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma. Cancer Cell Int 2022;22:295. [PMID: 36167542 DOI: 10.1186/s12935-022-02715-7] [Reference Citation Analysis]
3 Tang S, Zhao L, Wu X, Wang Z, Cai L, Pan D, Li Y, Zhou Y, Shen Y. Identification of a Novel Cuproptosis-Related Gene Signature for Prognostic Implication in Head and Neck Squamous Carcinomas. Cancers 2022;14:3986. [DOI: 10.3390/cancers14163986] [Reference Citation Analysis]
4 Guo Y, Pan WK, Wang ZW, Su WH, Xu K, Jia H, Chen J. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis. Biomed Res Int 2021;2021:4532438. [PMID: 34917682 DOI: 10.1155/2021/4532438] [Cited by in F6Publishing: 1] [Reference Citation Analysis]